Comparison of idarubicin + ara-C–, fludarabine + ara-C–, and topotecan + ara-C–based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

Regression Models and Life-Tables

1992 • 27,454 citations

Regression Models and Life-Tables

1972 • 27,145 citations

Robust Locally Weighted Regression and Smoothing Scatterplots

1979 • 10,049 citations

Modeling Survival Data: Extending the Cox Model

2000 • 7,620 citations

Evaluation of survival data and two new rank order statistics arising in its consideration.

1966 • 7,595 citations

Proportional hazards tests and diagnostics based on weighted residuals

1994 • 4,890 citations

International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes

1997 • 4,416 citations

Modern Applied Statistics with S-PLUS

1999 • 952 citations

The New s Language

1988 • 498 citations

Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy.

1993 • 331 citations

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

1994 • 299 citations

Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy

1997 • 238 citations

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

1999 • 202 citations

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

1999 • 180 citations

Fludarabine and Arabinosylcytosine Therapy of Refractory and Relapsed Acute Myelogenous Leukemia

1993 • 159 citations

Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

1999 • 138 citations

The use of response-adaptive designs in clinical trials

1993 • 109 citations

High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

2001 • 53 citations

Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.

1993 • 19 citations

Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy

1999 • 9 citations